<DOC>
	<DOCNO>NCT00420043</DOCNO>
	<brief_summary>This study evaluate effect food relative bioavailability single dose imatinib give 800 mg modify release tablet , compare twice-daily dos 400 mg film-coated tablet . There 8 day wash phase treatment 1 week safety period end study . Each participant receive four treatment .</brief_summary>
	<brief_title>Effect Food Bioavailability Modified Release Formulations Imatinib</brief_title>
	<detailed_description />
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion Healthy male female subject ( postmenopausal woman ) , 1865 year age Able communicate well investigator comply requirement study . Exclusion criterion Smokers within 3 month Subjects use prescription drug overthecounter ( OTC ) medication ( include herbal alternative medication ) within 3 week prior dose . Participation clinical investigation within 4 week prior dose longer required local regulation . A past medical history presence clinically significant ECG abnormality History acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease , treat treat ) . History medication predispose subject GI bleedings/cerebral hemorrhage . Women take biphosphonates ( Fosomax like drug ) History immunocompromised , include positive HIV test result . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . Females nurse infant . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Food effect</keyword>
	<keyword>bioavailability</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>STI571</keyword>
	<keyword>modify release formulation STI571</keyword>
	<keyword>CML</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Philadelphia Chromosome</keyword>
	<keyword>imatinib</keyword>
</DOC>